1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
FutureChem Co., Ltd.

FutureChem Co., Ltd.

KKRX:220100
8,990.00
KRW
+2,070.00
(+29.91%)
-456.85EPS
182.18BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
164.94
311.94
236.25
259.11
483.23
690.14
798.92
590.59
631.29
606
748.98
807.13
848.03
Basic EPS, GAAP
-916.5
-4,242.13
-3,966.17
-388.07
-1,026.27
-453.64
-1,675.79
-170.88
-700.86
-291.07
-407.88
-486.39
-459.03
Free Cash Flow per Basic Share
-1,165.33
-564.43
-435.71
-772.23
-1,004.31
-838.33
-419.43
-646.1
-580.78
-366.19
-220.49
-473.58
-603.53
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-716.92
-2,739.38
2,724.13
2,349.85
1,390.16
943.15
2,259.17
2,612.58
3,038.98
2,763.13
2,356.28
2,333.66
2,344.66
Tangible Book Value per Share
-871.8
-2,923.62
2,626.17
1,775.85
1,319.44
879.7
2,219.94
2,505.19
2,907.53
2,590.6
2,110.65
2,004.39
1,966.51
Basic Weighted Avg Shares
4
5
7
12
12
12
14
20
20
23
23
23
24
Sales/Revenue/Turnover
703
1,447
1,625
2,998
5,635
8,167
11,013
11,818
12,574
13,968
17,293
18,671
20,587
Operating Margin (%)
-128.69
-162.28
-238.98
-151.02
-128.88
-67.72
-43.72
-66.8
-102.85
-60.19
-54.73
-41.51
-45.51
Depreciation Expense
193
378
641
996
2,173
3,341
4,084
4,572
4,608
5,656
6,136
5,169
4,597
Net Income, GAAP
-3,905
-19,674
-27,286
-4,491
-11,969
-5,368
-23,101
-3,420
-13,959
-6,709
-9,418
-11,251
-11,143
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-555.66
-1,359.9
-1,678.83
-149.77
-212.38
-65.73
-209.76
-28.93
-111.02
-48.03
-54.46
-60.26
-54.13
Working Capital
-53
8,181
23,395
12,690
28,457
-305
30,181
26,917
31,583
28,363
23,729
19,961
20,573
LT Debt
1,866
4,786
- -
4,736
29,992
14,904
15,634
11,295
1,923
2,620
1,808
2,678
2,107
Total Equity
-3,792
-14,490
31,533
27,201
16,873
11,471
43,615
52,915
70,283
63,914
54,517
54,831
55,111
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-15.29
-54.83
-38.87
-84.72
-7.12
-22.73
-10.02
-15.94
-20.64
-20.36

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,807
2,885
3,264
LT Borrowings
- -
- -
2,107
LT Finance Leases
2,678
2,643
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
576,427
347,912
182,177

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
34,563
30,169
29,358
Cash, Cash Equivalents & STI
26,534
23,921
22,772
Accounts Receivable, Net
5,334
3,261
3,828
Inventories
1,561
2,084
1,674
Total Current Liabilities
14,603
11,882
8,785
Payables & Accruals
- -
- -
- -
ST Debt
4,807
2,885
3,264
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.02%
6.19%
0.58%
Free Cash Flow
34.82%
32.31%
115.18%
Net Income, GAAP
62.78%
46.18%
19.47%
Sales/Revenue/Turnover
32.11%
11.31%
7.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,437
3,433
4,185
6,239
17,293
2025
5,078
3,640
3,792
6,162
18,671
2026
6,362
4,272
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-81.38
-149.36
-153.19
-20.25
-407.88
2025
-106.28
112.02
-165.71
-275.47
-486.39
2026
-89.06
98.62
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dae-Yoon Ji
Full Time Employees
94
Sector
Health technology
Industry
Pharmaceuticals: other
Address
PyeongHwa Building Seoul SL South Korea 04794
IPO Date
Dec 1, 2016
Website
futurechem.co.kr
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
FutureChem Co.,Ltd operates as a leading developer and supplier of advanced radiopharmaceuticals, primarily targeting diagnostics and therapeutics within the healthcare sector. The company provides critical imaging agents, including PDVUE, a positron emission tomography (PET) diagnostic for Parkinson's disease, and Alzavue, a PET agent for identifying Alzheimer's disease in Korea. It also offers [18F]FDG and [18F]FLT for various cancer detection applications. Beyond its commercialized offerings, FutureChem is actively progressing a robust pipeline of novel radiopharmaceuticals. This includes 18F-FC303, a diagnostic PET compound designed for prostate cancer, and 177Lu-FC705, a therapeutic agent for prostate cancer, both of which are undergoing clinical evaluations and global partnership expansions. Further pipeline candidates encompass 18F-FMT for brain tumor imaging, 18F-FC505 for atherosclerotic plaque diagnosis, and 18F-FC211, an additional diagnostic for Alzheimer's disease. The firm, established in 1999, maintains its headquarters in Seoul, South Korea.